| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186344 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Jul, 2025
(1 year, 2 months from now) | |
| US8697748 | ULTRAGENYX PHARM INC | Glycogen or polysaccharide storage disease treatment method |
Apr, 2029
(5 years from now) | |
Dojolvi is owned by Ultragenyx Pharm Inc.
Dojolvi contains Triheptanoin.
Dojolvi has a total of 2 drug patents out of which 0 drug patents have expired.
Dojolvi was authorised for market use on 30 June, 2020.
Dojolvi is available in liquid;oral dosage forms.
Drug patent challenges can be filed against Dojolvi from 30 June, 2024.
The generics of Dojolvi are possible to be released after 28 April, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-311) | Jun 30, 2027 |
| New Chemical Entity Exclusivity(NCE) | Jun 30, 2025 |
Drugs and Companies using TRIHEPTANOIN ingredient
NCE-1 date: 30 June, 2024
Market Authorisation Date: 30 June, 2020
Treatment: NA
Dosage: LIQUID;ORAL
More Information on Dosage
DOJOLVI family patents
